OCGN Ocugen Inc: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
Ocugen, Inc. (OCGN) focuses on treating retinal pathologies and combating infections, relying on reimbursements from insurance companies and government agencies. The company is advancing ophthalmological gene therapy through partnerships with research centers and the acquisition of DNA platforms. However, risks persist regarding test results and high R&D costs, which are funded through equity offerings. The EV/EBITDA market trend recorded a value of 0.00.
ocugen.com - analytical breakdowns and key metrics (OCGN)
- current price and projected stock value:
- company stock capitalization data:
- book value of equity indicators:
- company total debt and liquidity indicators:
- net income and valuation multiples indicators:
OCGN - Net Income|Projected Future Earnings Ocugen, Inc.|OCGN - Market Cap to Net Income Ratio|Future Price to Earnings Ocugen, Inc.|OCGN - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Ocugen Pharma|OCGN - Operating profit before amortization|Earnings per share for the last twelve months Ocugen|OCGN - Earnings per share for the last 12 months|Quarterly EPS earnings growth ocugen.com|OCGN - Earnings growth in current year|Net earnings per share growth forecast for next year Ocugen, Inc.
- company sales and revenue statistics:
Analysis of all company metrics:Ocugen Corp (OCGN)
The market assesses Ocugen, Inc. (OCGN) as a high-risk asset with breakthrough potential in gene therapy and vaccines. The multiple compares the total enterprise value, including net debt, to EBITDA, measuring the payback period for all investments. By analyzing the dynamics of the base EV/EBITDA multiple, an investor can observe the valuation's reaction to the formation of clinical alliances. This determines the financial stability of Ocugen, Inc. (OCGN) in the absence of direct product analogues.
Analysis of competing companies
EV/EBITDA Multiple TEM (tempus.com)|Qiagen Corp (QGEN) - Company Value to EBITDA|IONS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|RGEN (repligen.com) - Enterprise Value to Operating Income Before Depreciation|RNA (Avidity Biosciences, Inc.) - Enterprise Value to EBITDA Ratio|CRISPR Therapeutics Inc - Business Value to Operating Income Before Depreciation|WGS (Sema4) - EV/EBITDA Multiple|Ultragenyx Corp (RARE) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Beam Therapeutics Inc. (BEAM)|sarepta.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple TWST (Twist Bioscience, Inc.)|TXG - Enterprise Value to EBITDA Ratio|NTLA: Enterprise Value to EBITDA Ratio|Total Company Value to Operating Income Before Depreciation Ratio Stoke Corp STOK|BioLife Solutions, Inc. (BLFS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA wavelifesciences.com (WVE)|MAZE (Maze Therapeutics) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Sionna Therapeutics, Inc. (SION)|EV/EBITDA Multiple PRME|Taysha Corp (TSHA) - Enterprise Value to EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization uniQure N.V. QURE|MGTX: Enterprise Value to Operating Income Before Depreciation|REGENXBIO - EV/EBITDA Multiple|SLDB (Solid Biosciences Inc) - Enterprise Value to Operating Income Before Depreciation|Pacific Biosciences of California (PACB) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation BNTC|DSGN (Design Therapeutics) - EV/EBITDA Multiple|EV/EBITDA Multiple rocketpharma.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization 4D Molecular Therapeutics, Inc. (FDMT)|LXEO - Company Value to EBITDA|EV/EBITDA Multiple KRRO (Korro Bio)|EDIT - Enterprise Value to EBITDA Ratio|SLN: Enterprise Value to EBITDA Ratio|PRQR - EV/EBITDA Multiple|CDXS: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Sangamo Therapeutics Inc. SGMO|NAUT (Nautilus Biotechnology, Inc.) - EV/EBITDA Multiple|Company Value to EBITDA Metagenomi Therapeutics MGX|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Precision BioSciences (DTIL)|generationbio.com - Enterprise Value to Operating Income Before Depreciation|Boundless Bio - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation XCUR|Celsion Corporation - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Phio Pharmaceuticals PHIO|mustangbio.com (MBIO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation RNAZ|BNGO (Bionano Genomics Inc.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Applied DNA Sciences Inc (APDN)|Enterprise Value to EBITDA Ratio BLUE (Bluebird Bio)|Total Company Value to Operating Income Before Depreciation Ratio immunoprecise.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Omega Therapeutics OMGA|singulargenomics.com (OMIC) - Company Value to EBITDA|Regulus Therapeutics Inc. - EV/EBITDA Multiple|Syros Pharmaceuticals Inc. (SYRS) - Enterprise Value to EBITDA Ratio|TBIO: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple TRACON Pharmaceuticals, Inc TCON|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Unity Biotechnology
